Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 8,509 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control Group Clear all
Terminated Not applicable Interventional Results available

Transcranial Direct Current Stimulation, Improve Functional Motor Recovery, Affected Arm

NCT01201629
View directory record Official record
Conditions
Brain Infarction, Brain Ischemia
Interventions
t DC stimulation, tDCStimulation
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
19 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 22, 2026, 5:13 PM EDT
Completed Phase 3 Interventional Results available

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

NCT04456673
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 85 Years
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
92
States / cities
Cullman, Alabama • Jasper, Alabama • Scottsboro, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 22, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

NCT05802173
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
North Little Rock, Arkansas • Rolling Meadows, Illinois • Plainfield, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 22, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients

NCT01197794
View directory record Official record
Conditions
Asthma Patients
Interventions
AZD1981, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Fullerton, California • Los Angeles, California • Mission Viejo, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 22, 2026, 5:13 PM EDT
Completed Phase 3 Interventional Results available

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

NCT01813422
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
59
States / cities
Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 22, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

NCT01756898
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
5 mg ASB17061, Placebo, 10 mg ASB17061, 20 mg ASB17061
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 65 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 22, 2026, 5:13 PM EDT
Completed Phase 3 Interventional

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

NCT00064402
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
Interventions
arformoterol tartrate inhalation solution, Salmeterol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
65
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 22, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

NCT03934099
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
LC350189 formulated capsule, Placebo
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
34
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 22, 2026, 5:13 PM EDT
Completed Not applicable Interventional Results available

Study Evaluated the Effectiveness of Milnacipran to Reduce Pain Levels in Individuals With Chronic Migraine

NCT01393522
View directory record Official record
Conditions
Chronic Migraine
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Timothy Smith
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
St Louis, Missouri • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 22, 2026, 5:13 PM EDT
Completed Phase 2 Interventional

Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis

NCT00539929
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
E6201 0.005%, E6201 0.01%, E6201 0.03%, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Hot Springs, Arkansas • San Diego, California • Boise, Idaho + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 22, 2026, 5:13 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult Subjects

NCT04104399
View directory record Official record
Conditions
Migraine
Interventions
XC101-D13H, Placebo
Drug
Lead sponsor
Xoc Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 22, 2026, 5:13 PM EDT
Recruiting Not applicable Interventional

Matching Treatments to Cognitive Deficits in Offenders With Substance Use Disorders

NCT06981351
View directory record Official record
Conditions
Antisocial Behavior
Interventions
Attention to Context (ATC) training, Affective Cognitive Control (ACC) training
Behavioral
Lead sponsor
The Mind Research Network
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 22, 2026, 5:13 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

NCT03817502
View directory record Official record
Conditions
Schizophrenia
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
Gedeon Richter Plc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Culver City, California • Atlanta, Georgia • Bloomfield Hills, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 22, 2026, 5:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Oral Microbiome and Pancreatic Cancer

NCT03302637
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
16S rRNA gene sequencing assay
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years to 74 Years
Enrollment
732 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 22, 2026, 5:13 PM EDT
Not listed Phase 3 Interventional

Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome

NCT02858453
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome, Painful Bladder Syndrome, Chronic Interstitial Cystitis
Interventions
AQX-1125 100 mg, AQX-1125 200 mg, Placebo
Drug
Lead sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
56
States / cities
Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Oct 22, 2026, 5:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Behavioral Intervention Study for Better Breast and Cervical Cancer Control for Korean American Women

NCT00857636
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer
Interventions
Health literacy, health message
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Ellicott City, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Oct 22, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Neuroscience-Informed Treatment Development for Adolescent Alcohol Use

NCT03238300
View directory record Official record
Conditions
Alcohol Drinking, Control
Interventions
N-Acetylcysteine, Placebo Oral Capsule
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
15 Years to 19 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 22, 2026, 5:13 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer

NCT03042611
View directory record Official record
Conditions
Gastric Cancer, Gastric Adenocarcinoma
Interventions
Rivoceranib, Placebo
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Rogers, Arkansas • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 22, 2026, 5:13 PM EDT
Terminated Phase 3 Interventional

Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas

NCT03582007
View directory record Official record
Conditions
Pneumonia
Interventions
Murepavadin, One anti-pseudomonal antibiotic
Drug
Lead sponsor
Polyphor Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Iowa City, Iowa • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 22, 2026, 5:13 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Gabapentin for Perioperative Pain Relief in Surgical Abortion

NCT04292171
View directory record Official record
Conditions
Pain Control
Interventions
Gabapentin, Placebos
Drug
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years and older · Female only
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 22, 2026, 5:13 PM EDT
Recruiting Phase 3 Interventional

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

NCT07197944
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Glepaglutide, Placebo
Drug · Other
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
Chicago, Illinois • St Louis, Missouri • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 5:13 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT02565511
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 22, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

Sitagliptin for Reducing Inflammation and Immune Activation

NCT02513771
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Sitagliptin, Placebo for sitagliptin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Los Angeles, California • Torrance, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 22, 2026, 5:13 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

NCT03689244
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 85 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 22, 2026, 5:13 PM EDT